About Us: Funding

"Cell-cell Communication during melanoma progression"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA76674), Years 9-14, Period: December 5, 1997 to March 30, 2011.

"Experimental transformation of human melanocytes in vivo"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA80999), Years 1-5, Period: April 1, 1999 to March 30, 2009.

"Biology of Melanoma Metastasis"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: R01 (CA47159), Years 16-20, Period: April 1, 2003 to March 31, 2008.

"Human Melanoma: Etiology, Progression, and Therapy"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project (CA25874), Years 25-29, Period: April1, 2005 to March 31, 2010.
Subproject 1 (Meenhard Herlyn): "The microenvironment in melanoma development and progression".

"SPORE Skin Cancer"
Director: Meenhard Herlyn
Agency: National Cancer Institute
Type: P50-SPORE [Specialized Program of Research Excellence] (CA93372), Years 1-7, Period: Oct. 1, 2001 to June 30, 2009.
Project 3 (David Elder and Meenhard Herlyn, Co-Leaders): “Gene expression of experimentally induced human melanocytic lesions to define new markers for atypical nevi and primary melanomas from patients”.

"Mechanisms of esophageal carcinogenesis"
Principal Investigator: Anil Rustgi, Co-Principal Investigator: Meenhard Herlyn
Type: P01-CA098101, Years 1-5, 2003-2008
Project 2 (Meenhard Herlyn): “Epithelial-stromal interactions in normal esophagus homeostasis and tumor development”.

NCI-sponsored Tumor Microenvironment Training Site: Techniques in the Establishment and Manipulation of Organotypic Model Systems
Principal Investigator: Meenhard Herlyn
Agency:NIH/NCI
Type: Contract, August 2005-July 2007

A new program to train established and new NCI-funded investigators (or nominated post-doctoral fellows in their laboratories) in establishing, maintaining, manipulating and characterizing a variety of organotypic and/or orthotopic models of human cancer.

N/A (Dr. M. Herlyn), October /05-December 2006
GlaxoSmithKline
Development of Spheroid Technology

N/A (Dr. M. Herlyn), 2003 - 2006
SULLIVAN FOUNDATION
Melanoma Research

"Targeted therapies in melanoma"
Principal Investigator: Meenhard Herlyn
Agency: National Cancer Institute
Type: P01-Program Project, pending
Subproject 1 (Meenhard Herlyn): "Targeting the MAPK and PI3K pathways".


Core Activities:

  1. ”Administrative Core A" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1990-2010.
  2. ”Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
  3. “Administrative Core A" for PO1 on Targeted Therapies in Melanoma, Pending, M. Herlyn, P.I.,
  4. Administrative Core A" for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
  5. Developmental Research Projects for SPORE on Skin Cancer, CA93372, M. Herlyn, P.I., 2001-2009.
  6. "Cell Biology Core C" for Melanoma Program Project, CA 25874, M. Herlyn P.I., 1990-2010.
  7. "Cell Culture" for Center for Molecular Studies in Digestive and Liver Disease, P30 DK50306. A. Rustgi, P.I., 2001-2006.
  8. "Cell Biology Core C" for PO1 ‘Targeted therapy in melanoma”, pending.